Topic

Articles

Life sciences companies are collaborating more with technology enterprises, universities, and other groups, which is changing the landscape of the industry.

As the Life Sciences Industry Transforms, New Risks Emerge

Barnes discusses alternative reimbursement plans for expensive, one-off therapies.

Q&A With Kim Barnes, Executive Vice President at Phacilitate

Environmental, social, and governance (ESG) standards are becoming more important for modern investors.

How to Make Sure Your Corporate Pharmaceutical ESG Strategy Is Appealing to Younger Generations

Corrigan discusses the importance of a patient-centric approach.

Q&A With ConnectiveRx CEO Jim Corrigan

VP, late development, immunology at The Janssen Pharmaceutical Companies of Johnson & Johnson.

Patients with Crohn's disease and ulcerative colitis face a high disease burden.

The Complementary Role of Real-World Evidence and Clinical Trials in Addressing Unmet Needs for IBD Patients

Senior manager, advisory life sciences operation transformation practice, Grant Thornton

With heightened government scrutiny on educational forums, biopharma manufacturers need a sound framework that demonstrates they are following best practices.

Cracking Down on Speaker Programs

A proactive and tailored compliance department—with the nimbleness to adapt strategies on the fly—is a critical shield for life sciences companies during government investigations.

Dynamic Compliance: The Best Defense for Pharma

As director of corporate strategy for Novartis, Kamenska defines direction for the company’s overall enterprise. Here, she discusses how the pandemic and recent market events are shaping these strategies. 

Q&A With Anastasiia Kamenska, director of corporate strategy, Novartis

Employees must be able to retain information and remain engaged to keep pace with highly regulated industry.

Learning and Development Is the Key to Compliance in Life Sciences

We may be only at the beginning of outcome-measured, value-based healthcare, but this is a chance for pharma organizations to show their mettle as roles are redefined and definitions of ‘value’ are agreed, says Gérard Klop of Vintura.